News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Paul Bunn, MD, University of Colorado Cancer Center

Articles by Paul Bunn, MD, University of Colorado Cancer Center

Reducing the Impact of Chemotherapy-Induced Myelosuppression

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

CDK4/6 Inhibitors & Myelopreservation in Other Cancers

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

CDK4/6 Inhibitors for SCLC: Trials of Interest

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

Chemotherapy-Induced Myelosuppression in SCLC: CDK4/6 Inhibition

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

Analyses of CDK4/6 Inhibitors for Myelopreservation

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

CDK4/6 Inhibitors and Myelopreservation

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

Chemotherapy-Induced Myelosuppression & COVID-19

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

Management of Chemo-Induced Myelosuppression

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

Chemotherapy Use & Chemotherapy-Induced Myelosuppression

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Development of KRAS G12C-Targeted Therapy in NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Systemic Therapy for KRAS+ Advanced NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Counseling Patients With NSCLC When KRAS is Detected

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Testing for KRAS Mutations in NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

KRAS Mutations in Solid Tumors

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Current Management of Oncogene-Driven NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Latest Updated Articles

Analyses of CDK4/6 Inhibitors for Myelopreservation
Published: September 16th 2020 | Updated:
Counseling Patients With NSCLC When KRAS is Detected
Published: August 3rd 2020 | Updated:
Testing for KRAS Mutations in NSCLC
Published: August 3rd 2020 | Updated:
CDK4/6 Inhibitors & Myelopreservation in Other Cancers
Published: September 16th 2020 | Updated:
Reducing the Impact of Chemotherapy-Induced Myelosuppression
Published: September 16th 2020 | Updated:
Current Management of Oncogene-Driven NSCLC
Published: August 3rd 2020 | Updated:

Trending on OncLive

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL

Oncology Fellows Highlights 2025 ESMO Fellowship Winners